Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 4/2013

01.04.2013 | Rapid Communication

Induction of tumor stem cell differentiation—novel strategy to overcome therapy resistance in gastric cancer

verfasst von: Derek Zieker, Sarah Bühler, Zeynep Üstündag, Ingmar Königsrainer, Sebastian Manncke, Khaled Bajaeifer, Jörg Vollmer, Falko Fend, Hinnak Northoff, Alfred Königsrainer, Jörg Glatzle

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Metastases are a frequent finding in gastric cancer and are associated with poor prognosis. A recently discovered link between metabolic changes, differentiation, and therapy resistance due to tumor stem cells could depict a novel approach in cancer research and therapy. Phosphoglycerate kinase 1 (PGK1) is a metabolic enzyme and is known to be involved in enabling gastric cancer cells to be invasive and to disseminate. In this study, we investigated if PGK1 is a promising candidate in inducing stem cell differentiation in gastric cancer.

Materials and methods

MKN45 gastric cancer cells were used due to their known cancer stem cell population, which is defined by the surface marker CD44. MKN45 cells were separated between CD44+ and CD44− cells and, in equal parts, incubated with shRNA anti-PGK1 using fluorescence-activated cell sorting (FACS) analysis; they were then injected into nude mice to evaluate their tumor growth behavior in vivo. Further, the invasive potential of gastric cancer cells was evaluated in vitro using the xCelligence analyzing system.

Results

CD44+ gastric cancer cells treated with and without shRNA anti-PGK1 were capable to cause tumor growth in vivo, whereas tumor growth in CD44+ cells treated with shRNA anti-PGK1 was considerably smaller in comparison with that in CD44+ cells without treatment. CD44− cells did not show any noticeable tumor growth in vivo. By targeting PGK1, the invasive potential of gastric cancer cells was impressively reduced in vitro. In all our cells, which were targeted with shRNA anti-PGK1, we did not find any change that is in accordance with the phenotype of the cells using FACS analysis.

Conclusions

Our findings suggest that targeting the key metabolic enzyme PGK1 in gastric cancer cells may open a new chapter in cancer treatment, which is well worth for further exploration in combination with recent chemotherapy, and might be a promising possibility to overcome therapy resistance in gastric cancer.
Literatur
2.
Zurück zum Zitat Rosen JM, Jordan CT (2009) The increasing complexity of the cancer stem cell paradigm. Science 324(5935):1670–1673PubMedCrossRef Rosen JM, Jordan CT (2009) The increasing complexity of the cancer stem cell paradigm. Science 324(5935):1670–1673PubMedCrossRef
3.
Zurück zum Zitat Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645–648PubMedCrossRef Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645–648PubMedCrossRef
4.
Zurück zum Zitat Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8(10):755–768PubMedCrossRef Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8(10):755–768PubMedCrossRef
5.
Zurück zum Zitat Sullivan JP, Minna JD, Shay JW (2010) Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 29(1):61–72PubMedCrossRef Sullivan JP, Minna JD, Shay JW (2010) Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 29(1):61–72PubMedCrossRef
6.
Zurück zum Zitat Tennant DA, Duran RV, Boulahbel H, Gottlieb E (2009) Metabolic transformation in cancer. Carcinogenesis 30(8):1269–1280PubMedCrossRef Tennant DA, Duran RV, Boulahbel H, Gottlieb E (2009) Metabolic transformation in cancer. Carcinogenesis 30(8):1269–1280PubMedCrossRef
7.
Zurück zum Zitat Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8(6):519–530PubMedCrossRef Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8(6):519–530PubMedCrossRef
8.
Zurück zum Zitat Bracha AL, Ramanathan A, Huang S, Ingber DE, Schreiber SL (2010) Carbon metabolism-mediated myogenic differentiation. Nat Chem Biol 6(3):202–204PubMedCrossRef Bracha AL, Ramanathan A, Huang S, Ingber DE, Schreiber SL (2010) Carbon metabolism-mediated myogenic differentiation. Nat Chem Biol 6(3):202–204PubMedCrossRef
9.
Zurück zum Zitat Wang J, Zhou J, Wu GS (2007) ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res 67(24):11933–11941PubMedCrossRef Wang J, Zhou J, Wu GS (2007) ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res 67(24):11933–11941PubMedCrossRef
10.
Zurück zum Zitat Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, Seiden MV (2002) Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 22(4):1933–1941PubMed Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, Seiden MV (2002) Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 22(4):1933–1941PubMed
11.
Zurück zum Zitat Hwang T, Liang Y, Chien K, Yu J (2006) Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 6(7):2259–2272PubMedCrossRef Hwang T, Liang Y, Chien K, Yu J (2006) Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 6(7):2259–2272PubMedCrossRef
12.
Zurück zum Zitat Zhang D, Tai LK, Wong LL, Chiu L, Sethi SK, Koay ESC (2005) Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4(11):1686–1696PubMedCrossRef Zhang D, Tai LK, Wong LL, Chiu L, Sethi SK, Koay ESC (2005) Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4(11):1686–1696PubMedCrossRef
13.
Zurück zum Zitat Zieker D, Konigsrainer I, Traub F, Nieselt K, Knapp B, Schillinger C, Stirnkorb C, Fend F, Northoff H, Kupka S, Brucher BLDM, Konigsrainer A (2008) PGK1 a potential marker for peritoneal dissemination in gastric cancer. Cell Physiol Biochem 21(5–6):429–436PubMedCrossRef Zieker D, Konigsrainer I, Traub F, Nieselt K, Knapp B, Schillinger C, Stirnkorb C, Fend F, Northoff H, Kupka S, Brucher BLDM, Konigsrainer A (2008) PGK1 a potential marker for peritoneal dissemination in gastric cancer. Cell Physiol Biochem 21(5–6):429–436PubMedCrossRef
14.
Zurück zum Zitat Zieker D, Konigsrainer I, Tritschler I, Loffler M, Beckert S, Traub F, Nieselt K, Buhler S, Weller M, Gaedcke J, Taichman RS, Northoff H, Brucher BLDM, Konigsrainer A (2010) Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. Int J Cancer 126(6):1513–1520PubMed Zieker D, Konigsrainer I, Tritschler I, Loffler M, Beckert S, Traub F, Nieselt K, Buhler S, Weller M, Gaedcke J, Taichman RS, Northoff H, Brucher BLDM, Konigsrainer A (2010) Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. Int J Cancer 126(6):1513–1520PubMed
15.
Zurück zum Zitat Zieker D, Konigsrainer I, Weinreich J, Beckert S, Glatzle J, Nieselt K, Buhler S, Loffler M, Gaedcke J, Northoff H, Mannheim JG, Wiehr S, Pichler BJ, von Weyhern C, Brucher BLDM, Konigsrainer A (2010) Phosphoglycerate kinase 1 promoting tumor progression and metastasis in gastric cancer - detected in a tumor mouse model using positron emission tomography/magnetic resonance imaging. Cell Physiol Biochem 26(2):147–154PubMedCrossRef Zieker D, Konigsrainer I, Weinreich J, Beckert S, Glatzle J, Nieselt K, Buhler S, Loffler M, Gaedcke J, Northoff H, Mannheim JG, Wiehr S, Pichler BJ, von Weyhern C, Brucher BLDM, Konigsrainer A (2010) Phosphoglycerate kinase 1 promoting tumor progression and metastasis in gastric cancer - detected in a tumor mouse model using positron emission tomography/magnetic resonance imaging. Cell Physiol Biochem 26(2):147–154PubMedCrossRef
16.
Zurück zum Zitat Takaishi S, Okumura T, Tu S, Wang SSW, Shibata W, Vigneshwaran R, Gordon SAK, Shimada Y, Wang TC (2009) Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27(5):1006–1020PubMedCrossRef Takaishi S, Okumura T, Tu S, Wang SSW, Shibata W, Vigneshwaran R, Gordon SAK, Shimada Y, Wang TC (2009) Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27(5):1006–1020PubMedCrossRef
18.
Zurück zum Zitat Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8(20):3274–3284PubMedCrossRef Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8(20):3274–3284PubMedCrossRef
19.
Zurück zum Zitat Petrie K, Zelent A, Waxman S (2009) Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 16(2):84–91PubMedCrossRef Petrie K, Zelent A, Waxman S (2009) Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 16(2):84–91PubMedCrossRef
Metadaten
Titel
Induction of tumor stem cell differentiation—novel strategy to overcome therapy resistance in gastric cancer
verfasst von
Derek Zieker
Sarah Bühler
Zeynep Üstündag
Ingmar Königsrainer
Sebastian Manncke
Khaled Bajaeifer
Jörg Vollmer
Falko Fend
Hinnak Northoff
Alfred Königsrainer
Jörg Glatzle
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 4/2013
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-013-1058-5

Weitere Artikel der Ausgabe 4/2013

Langenbeck's Archives of Surgery 4/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.